CoChat

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results: Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy406

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Figure 1 A nomogram is used to assign each of 11 prognostic factors with a point range from 0 to 100 in a graphic interface, based on the estimated regression coefficients from the final multivariable Cox proportional hazards model predicting overall survival (OS). The nomogram results match with the algorithm. The 1-, 2-, and 3-year survival probability versus total points were also generated to allow the clinical partition to predict OS. The nomogram was developed using SAS V R enterprise version 7.1 and is based on the following article: http://support.sas.com/ resources/papers/proceedings13/264-2013.pdf. Instructions to physicians: All of the 11 prognostic factors should be available before using this model. Start from the second top axis by identifying the number of bone metastases. Draw a vertical line to the points axis (top line) to represent the number of prognostic points the patients will receive for number of bone metastases. Do the same for the other prognostic variables. Once all prognostic points for the predictors have been determined, add up the prognostic points for each prognostic variable. On the basis of the total points, one can determine the 1-year survival probability by drawing a vertical line from the total points x -axis to the survival probability. The same process can be performed to estimate the 2-year and 3-year survival probability.
Figure 1 A nomogram is used to assign each of 11 prognostic factors with a point range from 0 to 100 in a graphic interface, based on the estimated regression coefficients from the final multivariable Cox proportional hazards model predicting overall survival (OS). The nomogram results match with the algorithm. The 1-, 2-, and 3-year survival probability versus total points were also generated to allow the clinical partition to predict OS. The nomogram was developed using SAS V R enterprise version 7.1 and is based on the following article: http://support.sas.com/ resources/papers/proceedings13/264-2013.pdf. Instructions to physicians: All of the 11 prognostic factors should be available before using this model. Start from the second top axis by identifying the number of bone metastases. Draw a vertical line to the points axis (top line) to represent the number of prognostic points the patients will receive for number of bone metastases. Do the same for the other prognostic variables. Once all prognostic points for the predictors have been determined, add up the prognostic points for each prognostic variable. On the basis of the total points, one can determine the 1-year survival probability by drawing a vertical line from the total points x -axis to the survival probability. The same process can be performed to estimate the 2-year and 3-year survival probability.CC-BY-NC-ND · From the PDF
Figure 2 Analysis of overall survival based on the 11-variable model. Analyses in (A) high- and low-risk patients as stratified by median risk score and (B) high-, intermediate-, and low-risk patients as stratified by tertiles of the risk score. CI, confidence interval; NYR, not yet reached; REF, reference.
Figure 2 Analysis of overall survival based on the 11-variable model. Analyses in (A) high- and low-risk patients as stratified by median risk score and (B) high-, intermediate-, and low-risk patients as stratified by tertiles of the risk score. CI, confidence interval; NYR, not yet reached; REF, reference.CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Ferlay, 2016, GLOBOCAN 2012 v10 Cancer Incidence and Mortality Worldwide IARC CancerBase No 11

Cited by

See all 82

Metadata

Authors
Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A., & Beer, T. M.
Affiliations
  • Duke University (US)
  • Pfizer (United States) (US)
  • University of Washington (US)
  • Azienda Ospedaliera San Camillo-Forlanini (IT)
  • University of Alabama at Birmingham (US)
  • Cliniques Universitaires Saint-Luc (BE)
  • University of Basel (CH)
  • Université Paris-Sud (FR)
  • Astellas Pharma (Netherlands) (NL)
  • Astellas Pharma (United States) (US)
  • Oregon Health & Science University (US)
Corresponding author
Armstrong, A.J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-11
Volume
29
Issue
11
Pages
2200-2207
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2892249349
Cited by
71
References
31
Citations by year
2026: 7 · 2025: 8 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 16 · 2020: 7 · 2019: 6 · 2018: 2
FWCI
5.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
Funders
  • Astellas Pharma, Inc
  • Duke Cancer Center's P30 (CA014236)
  • US Department of Defense Prostate Cancer Clinical Trials Consortium
  • DOD
  • PCCTC (W81XWH-14-2-0179)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
metastatic castration-resistant prostate cancer, enzalutamide, prognostic model, overall survival, chemotherapy-naive patients, PREVAIL trial, risk stratification, androgen receptor antagonists, external validation
MeSH terms
Progression-Free Survival, Aged, Androgen Antagonists, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Male, Models, Biological, Nitriles, Phenylthiohydantoin, Prognosis, Biomarkers, Tumor, Proportional Hazards Models, Disease Progression, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. https://app.cochat.ai/papers/10.1093/annonc/mdy406
The paper
Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A., & Beer, T. M. (2018). Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdy406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.